Torrent Pharmaceuticals Limited

NSEI:TORNTPHARM Stock Report

Market Cap: ₹1.2t

Torrent Pharmaceuticals Past Earnings Performance

Past criteria checks 6/6

Torrent Pharmaceuticals has been growing earnings at an average annual rate of 13%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 7.8% per year. Torrent Pharmaceuticals's return on equity is 24%, and it has net margins of 16.1%.

Key information

13.0%

Earnings growth rate

12.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate7.8%
Return on equity24.0%
Net Margin16.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity

Dec 16
If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity

Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts

Oct 29
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts

Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing

Oct 24
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing

Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets

Jul 26
Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets

Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Apr 16
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Mar 03
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Feb 05
Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Jan 07
Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Revenue & Expenses Breakdown

How Torrent Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:TORNTPHARM Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24112,23818,02421,0760
30 Jun 24109,95817,35420,6760
31 Mar 24107,27816,56420,1660
31 Dec 23104,74214,94219,6620
30 Sep 23102,33213,43218,9320
30 Jun 2398,64212,69217,8420
31 Mar 2396,20212,45217,0520
31 Dec 2292,5808,31216,2330
30 Sep 2288,7507,97215,8830
30 Jun 2287,2108,01215,8330
31 Mar 2285,0807,77215,4830
31 Dec 2183,15812,18915,2270
30 Sep 2182,02812,66914,9770
30 Jun 2180,82812,60914,7170
31 Mar 2180,04612,51914,5970
31 Dec 2080,14312,41714,3500
30 Sep 2079,85311,95714,2600
30 Jun 2079,73311,29714,2100
31 Mar 2079,39310,24714,4210
31 Dec 1978,4885,59314,3980
30 Sep 1979,3385,54314,5380
30 Jun 1978,2284,89314,3880
31 Mar 1976,7284,36314,0380
31 Dec 1875,1418,16113,7430
30 Sep 1869,8916,28112,7830
30 Jun 1865,1216,53112,1830
31 Mar 1859,4986,78111,3530
31 Dec 1756,7276,55610,6740
30 Sep 1756,3878,26610,2840
30 Jun 1756,3878,29610,0440
31 Mar 1758,1579,3369,9340
31 Dec 1659,15410,01410,2330
30 Sep 1660,14410,6249,9130
30 Jun 1662,74413,6449,3930
31 Mar 1666,66917,3328,4240
31 Dec 1563,31516,29918,6530
30 Sep 1559,60513,13918,5830
30 Jun 1554,8659,43918,7230
31 Mar 1546,5357,5098,7720
31 Dec 1447,2478,64916,5100
30 Sep 1445,7178,55916,3100
30 Jun 1443,2677,70915,8900
31 Mar 1441,8476,63915,7700

Quality Earnings: TORNTPHARM has high quality earnings.

Growing Profit Margin: TORNTPHARM's current net profit margins (16.1%) are higher than last year (13.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TORNTPHARM's earnings have grown by 13% per year over the past 5 years.

Accelerating Growth: TORNTPHARM's earnings growth over the past year (34.2%) exceeds its 5-year average (13% per year).

Earnings vs Industry: TORNTPHARM earnings growth over the past year (34.2%) exceeded the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: TORNTPHARM's Return on Equity (24%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 13:10
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Torrent Pharmaceuticals Limited is covered by 60 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
null nullAntique Stockbroking Ltd.
Meeta ShettyAsian Markets Securities Private Limited